Ilia I. Ouspenski

Array ( [id] => 12566001 [patent_doc_number] => 10017575 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-10 [patent_title] => Antibody molecules having specificity for human OX40 [patent_app_type] => utility [patent_app_number] => 15/242135 [patent_app_country] => US [patent_app_date] => 2016-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 11 [patent_no_of_words] => 20075 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15242135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11471250 [patent_doc_number] => 20170058033 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'PD-L1 Antibodies' [patent_app_type] => utility [patent_app_number] => 15/239959 [patent_app_country] => US [patent_app_date] => 2016-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8687 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15239959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11443236 [patent_doc_number] => 20170044256 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS' [patent_app_type] => utility [patent_app_number] => 15/239569 [patent_app_country] => US [patent_app_date] => 2016-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 53 [patent_no_of_words] => 59864 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15239569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15784935 [patent_doc_number] => 10626174 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-21 [patent_title] => Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors [patent_app_type] => utility [patent_app_number] => 15/239524 [patent_app_country] => US [patent_app_date] => 2016-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 120 [patent_no_of_words] => 54719 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15239524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13354653 [patent_doc_number] => 20180228866 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 15/751117 [patent_app_country] => US [patent_app_date] => 2016-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15751117 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18559807 [patent_doc_number] => 11725041 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-15 [patent_title] => Immune-modulating compounds [patent_app_type] => utility [patent_app_number] => 16/324857 [patent_app_country] => US [patent_app_date] => 2016-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 13 [patent_no_of_words] => 46996 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16324857 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14422599 [patent_doc_number] => 10316089 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-11 [patent_title] => PD-1 antibodies [patent_app_type] => utility [patent_app_number] => 15/232026 [patent_app_country] => US [patent_app_date] => 2016-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9016 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15232026 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11290476 [patent_doc_number] => 20160340408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-24 [patent_title] => 'B7-RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR IMMUNOMODULATION' [patent_app_type] => utility [patent_app_number] => 15/229582 [patent_app_country] => US [patent_app_date] => 2016-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 39 [patent_no_of_words] => 43683 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15229582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11457154 [patent_doc_number] => 20170051060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-23 [patent_title] => 'Immunopotentiative Composition' [patent_app_type] => utility [patent_app_number] => 15/226848 [patent_app_country] => US [patent_app_date] => 2016-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 14084 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15226848 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11729317 [patent_doc_number] => 20170190759 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-06 [patent_title] => 'BSL2v2c2-Ig polypeptides' [patent_app_type] => utility [patent_app_number] => 15/218699 [patent_app_country] => US [patent_app_date] => 2016-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 48 [patent_no_of_words] => 76417 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15218699 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11122046 [patent_doc_number] => 20160319021 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-03 [patent_title] => 'Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Alzheimer\'s Disease' [patent_app_type] => utility [patent_app_number] => 15/212231 [patent_app_country] => US [patent_app_date] => 2016-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 21365 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15212231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11429092 [patent_doc_number] => 09567399 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2017-02-14 [patent_title] => 'Antibodies and immunocytokines' [patent_app_type] => utility [patent_app_number] => 15/211504 [patent_app_country] => US [patent_app_date] => 2016-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 27 [patent_no_of_words] => 92333 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15211504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15281805 [patent_doc_number] => 10513558 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-24 [patent_title] => Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof [patent_app_type] => utility [patent_app_number] => 15/209385 [patent_app_country] => US [patent_app_date] => 2016-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 54 [patent_no_of_words] => 124931 [patent_no_of_claims] => 77 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15209385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11304840 [patent_doc_number] => 09512227 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-06 [patent_title] => 'Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer\'s disease' [patent_app_type] => utility [patent_app_number] => 15/202493 [patent_app_country] => US [patent_app_date] => 2016-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 56 [patent_no_of_words] => 21388 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15202493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16833262 [patent_doc_number] => 11009509 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-18 [patent_title] => Anti-VISTA antibodies and fragments [patent_app_type] => utility [patent_app_number] => 15/738013 [patent_app_country] => US [patent_app_date] => 2016-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 111 [patent_no_of_words] => 25620 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15738013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11100911 [patent_doc_number] => 20160297880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-13 [patent_title] => 'Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Alzheimer\'s Disease' [patent_app_type] => utility [patent_app_number] => 15/190160 [patent_app_country] => US [patent_app_date] => 2016-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 21365 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15190160 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11336741 [patent_doc_number] => 20160362495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-15 [patent_title] => 'Human Monoclonal Antibodies to Programmed Death Ligand 1 (PD-L1)' [patent_app_type] => utility [patent_app_number] => 15/188860 [patent_app_country] => US [patent_app_date] => 2016-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 61 [patent_figures_cnt] => 61 [patent_no_of_words] => 44026 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15188860 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11350257 [patent_doc_number] => 20160368998 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-22 [patent_title] => 'FULLY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB' [patent_app_type] => utility [patent_app_number] => 15/174268 [patent_app_country] => US [patent_app_date] => 2016-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 11842 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15174268 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11588519 [patent_doc_number] => 20170112929 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/174213 [patent_app_country] => US [patent_app_date] => 2016-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 56 [patent_no_of_words] => 97082 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15174213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11304830 [patent_doc_number] => 09512216 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-06 [patent_title] => 'Use of TNFα inhibitor' [patent_app_type] => utility [patent_app_number] => 15/173191 [patent_app_country] => US [patent_app_date] => 2016-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 23897 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15173191 [rel_patent_id] =>[rel_patent_doc_number] =>)